

**PCR-/NAT *Pneumocystis jirovecii*
 (RV 560) Mai 2015**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1515601	∅	62	<i>Escherichia coli</i> K12
1515602	+++	61	<i>Pneumocystis jirovecii</i> (~ 1x10 ⁶ organisms /mL)
1515603	++	61	<i>Pneumocystis jirovecii</i> (~ 5x10 ⁴ organisms /mL)
1515604	∅	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n = 85</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>					
<i>Befund Result</i>	1515601	1515602	1515603	1515604	1515601	1515602	1515603	1515604		
Positiv	0	84	77	0	n.d.	0	0	0	0	
Negativ	81	0	4	83	nein no	81	84	84	83	
Fraglich Questionable	4	1	4	2	ja yes	4	1	1	2	

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
TIB Molbiol LightMix PJ [21] (n =13)	24	24 / 25 §	96	26	26 / 26	100
r-Biopharm RIDAGENE PJ [22] (n =15)	28	28 / 29 §	97	30	30 / 30	100
AmpliGnost PJ PCR Kit [23] (n =8)	16	16 / 16	100	16	16 / 16	100
Sacace PJ RealTM [24] (n =2)	4	4 / 4	100	3	3 / 3 §	100
Commercial assay / kit [27] (n =5)	8	8 / 8 §	100	7	7 / 7 §	100
<i>In house</i> PCR assay [28] (n = 41)	79	79 / 81 §	98	80	80 / 80 §	100
Andere / k.A. / other [29] (n = 2)	4	4 / 4	100	4	4 / 4	100

§ Due to reporting questionable results, the number of true results (denominator in the „relative“ column) has been reduced.